About the Project. The Babraham Institute is a world-leader in fundamental biological research investigating the systems that underpin development and healthy ageing. Read more
Discovery of novel modulators of T cell receptor signalling in cancer. In cancer and chronic infection, chronically stimulated T cells reduce their function through mechanisms that are not fully understood. Read more
The induction of immune responses to tumours can provide long-lasting protection from cancer. In this regard, T cells can suppress tumour growth by directly killing cancer cells and by producing inflammatory cytokines. Read more
CD4+Foxp3+ regulatory T-cells (Tregs) are the most well characterised suppressive cell type in the immune system, with potent roles in suppressing autoimmunity. Read more
Summary. Cytotoxic T cells have the capability of killing tumour target cells. However, this ability is commonly suppressed within the tumour microenvironment. Read more
Inflammatory arthritis (IA) can result from non-autoimmune diseases (like crystal arthritis) and from autoimmune diseases like rheumatoid arthritis (RA) and spondyloarthropathies (inc. Read more
About the research project. Epstein-Barr virus (EBV) is a double stranded DNA herpes virus that can have a profound effect on the immune system. Read more
T cell-based immunotherapy has revolutionised the treatment of many different types of cancer. However, to date, these treatments have not been successful or widely used for the treatment of brain tumours. Read more
Chimeric antigen receptor (CAR)-T therapies have demonstrated remarkable treatment outcomes and several CAR-T therapies now approved for treatment of haematological malignancies. Read more
Project Overview. Ongoing projects in the Teichmann team are generating scRNA-seq and chromatin accessibility profiles of thymic cells using the 10X multiome kit, combined with multiplex protein staining. Read more
Proteolysis-targeting chimeras (PROTACs) are a new class of drugs with immense potential across multiple therapeutic areas in drug development. Read more
*Offer only available for the duration of your active subscription, and subject to change. You MUST claim your prize within 72 hours, if not we will redraw.
Do you want hassle-free information and advice?
Create your FindAPhD account and sign up to our newsletter:
Find out about funding opportunities and application tips
Receive weekly advice, student stories and the latest PhD news
Hear about our upcoming study fairs
Save your favourite projects, track enquiries and get personalised subject updates
Due to your Facebook privacy settings, we were unable to create your account at this time. Please select another method to sign up.
We were unable to log you in with your Google account at this time. If you have third-party cookies blocked, please enable them, refresh, and try again.
or
Continue with Facebook
Create your account
We were unable to log you in with your Google account at this time. If you have third-party cookies blocked, please enable them, refresh, and try again.
Looking to list your PhD opportunities? Log in here.